In the realm of antibacterial drug development, the initial clarity of a drug's mechanism is pivotal, often determining the project's viability. Creative Biolabs is addressing this challenge by focusing on the nucleic acid synthesis pathway, a target that offers a broad antibacterial spectrum and reduced cross-resistance risks. This approach is exemplified by drugs like fluoroquinolones and rifamycins, which target DNA gyrase and RNA polymerase, respectively.
Creative Biolabs has expanded its mechanism identification services beyond traditional methods to include structural-level analyses. Utilizing substrate simulation, small molecule library docking, and de novo design strategies, the company aims to pinpoint and optimize enzyme active sites. This method allows for the identification of potential inhibitors through computational modeling before laboratory validation, streamlining the discovery process.
However, the journey from promising in vitro activity to a successful drug is fraught with pharmacokinetic hurdles. Recognizing this, Creative Biolabs integrates pharmacokinetic model construction early in development. This comprehensive approach employs both non-compartmental and compartmental modeling to simulate a drug's in vivo dynamics, offering insights into absorption, distribution, metabolism, and excretion. Such models not only predict a drug's half-life and optimize dosing regimens but also assess its druggability for IND submissions.
By advancing mechanism elucidation and pharmacokinetic modeling in tandem, Creative Biolabs aids clients in navigating the complex landscape of drug development. This dual focus helps in identifying effective inhibitors while forecasting their in vivo performance, thereby mitigating the risk of failure due to poor pharmacokinetics or toxicity. The company's strategy underscores the importance of a holistic approach to drug development, aiming to save time and resources while increasing the likelihood of success.
